DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0331402 A1 Lewyn-Briscoe Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0331402 A1 Lewyn-Briscoe Et Al US 2013 0331402A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0331402 A1 Lewyn-Briscoe et al. (43) Pub. Date: Dec. 12, 2013 (54) DOSING REGIMENASSOCATED WITH (60) Provisional application No. 61/256,696, filed on Oct. LONG-ACTING INUECTABLE 30, 2009. PALIPERDONE ESTERS (71) Applicant: Janssen Pharmaceutica NV, Beerse Publication Classification (BE) (51) Int. Cl. (72) Inventors: Peter H. Lewyn-Briscoe, Newtown, PA A 6LX3/59 (2006.01) (US); Christina Gassmann-Mayer, A619/00 (2006.01) Pennington, NJ (US); Srihari Gopal, (52) U.S. Cl. Belle Mead, NJ (US); David W. Hough, CPC ............. A6IK3I/519 (2013.01); A61 K9/0019 Wallingford, PA (US); Bart M. M. (2013.01) Remmerie, Gent (BE); Mahesh N. USPC ..................................................... S14/259.41 Samtani, Flemington, NJ (US) (73) Assignee: Janssen Pharmaceutica NV, Beerse (57) ABSTRACT (BE) Appl. No.: The present application provides a method for treating (21) 13/903,638 patients in need of psychiatric treatment, wherein said patient (22) Filed: May 28, 2013 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (62) Division of application No. 12/916,910, filed on Nov. ing treatment to paliperidone palmitate in a Sustained release 1, 2010, now abandoned. formulation. Patent Application Publication Dec. 12, 2013 Sheet 1 of 6 US 2013/0331402 A1 First-Orier Process Zero-Order Process Patent Application Publication Dec. 12, 2013 Sheet 2 of 6 US 2013/0331402 A1 25mg eq 50E. e e to 50mged issed dose of Wik 4, Patient feturns or k 5 issed dose of k & Patient eins of k 6 3 A 2 2024 issed dose on Wiki. Patient feturns on Wk 2 62 24 . 2 is 224 Time (week) Patent Application Publication Dec. 12, 2013 Sheet 3 of 6 US 2013/0331402 A1 (uffu) doeiuaguo genSeoid? Patent Application Publication Dec. 12, 2013 Sheet 4 of 6 US 2013/0331402 A1 {}{}}. (uffu) use. 83 iOC Patent Application Publication Dec. 12, 2013 Sheet 5 of 6 US 2013/0331402 A1 FIG. 5 Daily Extended Release Paliperidone invega 6 mg) 6-ing invegaswitched to 15G/4GGingeq. Pali-Palmitate ki---- N ikkilikilikiki ikikilikikilikkilikiki. Daily Extended Release Paliperidone (invega 6mo) TT 6-ing invega Switched over to 150 mg eq, Pai-Palmitate O .7 1 8 5 22 29 Time (day) Patent Application Publication Dec. 12, 2013 Sheet 6 of 6 US 2013/0331402 A1 F.G. 6 - 100 s E. 3. t g 1 S 9.O1 4 Doses of 50 ge i . < 0.01 - 100 s s SE 3 g 1 s O1 :::::::::100mge g aipeidone Paisitate 's < 0.01 Time (wk) US 2013/0331402 A1 Dec. 12, 2013 DOSING REGIMENASSOCATED WITH palmitate for treating patients is disclosed in US Patent Appli LONG-ACTING INUECTABLE cation Publication No. 20090163519. PALPERDONE ESTERS 0007 Paliperidone palmitate is an atypical antipsychotic drug administered by injection. Paliperidone palmitate may CROSS REFERENCE TO RELATED be administered at flexible injection sites including gluteal or APPLICATIONS deltoid muscle. Previous oil-based antipsychotic agents are 0001. This application is a divisional of U.S. patent appli indicated for gluteal muscle injection and may be associated cation Ser. No. 12/916,910, filed Nov. 1, 2010, pending, with pain on injection, which may cause undesired effects of which claims the benefit of U.S. Provisional Application needle phobia and perceived injection pain. This may reduce 61/256,696, filed on Oct. 30, 2009, the entire disclosures of patients’ acceptance towards these medications and result in which are hereby incorporated in their entirety. a negative influence on the clinical management of these patients. The administration of paliperidone palmitate at flex FIELD OF THE INVENTION ible injection sites may improve patients’ acceptance and compliance to psychotic treatment. 0002 This invention relates to a method for treating 0008. In addition, paliperidone palmitate provides ben patients in need of Switching treatment from other antipsy efits of Sustained dose release in plasma without significant chotic drug to long-acting injectable paliperidone palmitate concentration variation, regular monitor, reduced side effects formulations. and increased treatment efficacy. The administration of pali BACKGROUND OF THE INVENTION peridone palmitate may improve effectiveness of psychotic treatment. 0003 Antipsychotic medications are the mainstay in the 0009. Therefore, there may be an increasing demand to treatment of Schizophrenia, Schizoaffective disorder, and switch treatment of patients in need thereof from oral or Schizophreniform disorders. Conventional antipsychotics injectable antipsychotic drugs to paliperidone palmitate. Fur were introduced in the mid-1950s. These typical or first gen ther, there is a need to reinitiate a dosing regimen for patients eration drugs are usually effective in controlling the positive who misses their maintenance or stabilized dose. Thus, the symptoms of Schizophrenia, but are less effective in moder objective of the present application is to provide a dosing ating the negative symptoms or the cognitive impairment regimen of paliperidone palmitate for patients in need of a associated with the disease. Atypical antipsychotics or sec treatment Switching from other antipsychotic agents to pali ond generation drugs, typified by risperidone and Olanzapine, peridone palmitate. Another objective of the present applica were developed in the 1990s, and are generally characterized tion is to provide a dosing regimen of paliperidone palmitate by effectiveness against both the positive and negative symp for patients who have missed the monthly maintenance or toms associated with Schizophrenia. stabilized dosing regimen of paliperidone palmitate. 0004 Paliperidone palmitate is the palmitate ester of pali peridone (9-hydroxy-risperidone), a monoaminergic antago SUMMARY OF THE INVENTION nist that exhibits the characteristic dopamine D and seroto nin (5-hydroxytryptamine type 2A) antagonism of the second 0010. In one embodiment of the present application a dos generation, atypical antipsychotic drugs. Paliperidone is the ing regimen is provided for administering paliperidone major active metabolite of risperidone. Extended release palmitate to a patient in need of psychiatric treatment, (ER) osmotic controlled release oral delivery (OROS) pali wherein said patient misses a stabilized monthly maintenance peridone, as a tablet formulation, is marketed in the United dose for more than about 4 weeks and less than about 6 weeks, States (U.S.) for the treatment of schizophrenia and mainte comprising administering intramuscularly in the deltoid a nance of effect. first reinitiation loading dose of paliperidone as a paliperi 0005 Paliperidone palmitate is being developed as a long done palmitate formulated in a Sustained release formulation acting, intramuscular (i.m.), injectable aqueous nanosuspen on the first day of treatment; and administering intramuscu sion for the treatment of schizophrenia and other related larly in the gluteal a reinitiation maintenance dose of paliperi diseases that are normally treated with antipsychotic medica done as a paliperidone esterina Sustained release formulation tions. Because of extreme low water solubility, paliperidone on the 23" day to about the 37' day or between about 30+7 esters such as paliperidone palmitate dissolve slowly after an day after said first day of treatment. i.m. injection before being hydrolyzed to paliperidone and 0011. In another embodiment of the present application a made available in the systemic circulation. dosing regimen is provided for administering paliperidone 0006. Many patients with the mental illnesses achieve esters to a patient in need of psychiatric treatment, wherein symptom stability with available oral antipsychotic medica said patient misses a stabilized monthly maintenance dose for tions; however, it is estimated that up to 75% have difficulty more than about 6 weeks, comprising administering intra adhering to a daily oral treatment regimen, i.e. compliance muscularly in the deltoid a first reinitiation loading dose of problems. Problems with adherence often result in worsening paliperidone as a paliperidone palmitate formulated in a Sus of symptoms, Suboptimal treatment response, frequent tained release formulation on the first day of treatment; relapses and re-hospitalizations, and an inability to benefit administering intramuscularly in the deltoid a second reini from rehabilitative and psychosocial therapies. Paliperidone tiation loading dose of paliperidone as a paliperidone palmi palmitate injection has been developed to provide Sustained tate formulated in a sustained release formulation 1 week plasma concentrations of paliperidone when administered later (on the eighth day of treatment); and administering once monthly, which may greatly enhance compliance with intramuscularly in the gluteal a reinitiation maintenance dose dosing. Paliperidone palmitate formulated as an aqueous of paliperidone as a paliperidone ester in a Sustained release nanosuspension is described in U.S. Pat. Nos. 6,577.545 and formulation on about the 23" day to about the 37' day or 6,555,544. In addition, a dosing regimen of paliperidone between about 30+7 days after said first day of treatment. US 2013/0331402 A1 Dec. 12, 2013 0012. According to the present application, the first reini 0022 FIG. 5. Switching treatment from oral paliperidone tiation dose and the second reinitiation dose may be the same ER to paliperidone palmitate.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Haloperidol Versus Placebo for Schizophrenia
    Haloperidol versus placebo for schizophrenia Item Type Article Authors Irving, Claire B.; Adams, Clive E. Citation Irving, C. B., Adams, C. E. & Lawrie, S. (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, (4), pp.1-69. Download date 25/09/2021 21:20:50 Link to Item http://hdl.handle.net/20.500.12904/9860 Haloperidol versus placebo for schizophrenia (Review) Irving CB, Adams CE, Lawrie S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2006, Issue 4 http://www.thecochranelibrary.com Haloperidol versus placebo for schizophrenia (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 6 DISCUSSION ..................................... 10 AUTHORS’CONCLUSIONS . 11 ACKNOWLEDGEMENTS . 11 REFERENCES ..................................... 12 CHARACTERISTICSOFSTUDIES . 25 DATAANDANALYSES. 67 Haloperidol versus placebo for schizophrenia (Review) i Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Haloperidol versus placebo for schizophrenia Claire B Irving1, Clive E Adams1, Stephen Lawrie2 1Cochrane Schizophrenia
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Synthesis of 11-(Piperazin-1-Yl)-5H-Dibenzo [B
    ISSN: 0973-4945; CODEN ECJHAO E-Journal of Chemistry http://www.e-journals.net 2011, 8(4), 1747-1749 Synthesis of 11-(Piperazin-1-yl)-5H-dibenzo[b,e] [1,4]diazepine on Kilo Scale RAHUL S. KALHAPURE, BHUSHAN P. PATIL §, MAHANTESH N. JADHAV §, LAXMIKANT A. KAWLE § and SANJAY B. WAGH §,* Dept. of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga (East), Mumbai-400019 (M.S.), India §N.D.M.V.P.Samaj’s College of Pharmacy, Gangapur Road, Nashik-422005 (M.S.), India. [email protected] Received 26 January 2010; Accepted 22 April 2010 Abstract: A synthesis of 11-(piperazin-1yl)-5H-dibenzo[b,e][1,4]diazepine on kilo scale without any chromatographic purification step is reported. Key steps involved are Ullmann condensation, catalytic hydrogenation, and catalyzed cyclization. Keywords: Antipsychotics, Dibenzodiazepine, Titanium tetrakisamine complex, Clozapine, Ullmann condensation Introduction Dibenzodiazepine derivatives have attracted much attention from the medicinal chemistry community owing to their potential use in the treatment of psychiatric disorders. The drugs in current clinical use from this class are few in number. Some of them are clozapine, olanzapine and flumezapine. In past years large number of derivatives from this class have been synthesized and tested for their pharmacological actions like muscarinic agonistic and dopamine antagonistic activities 1-7. 11-(Piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine is a structural analogue of clozapine, an important atypical antipsychotic. Atypical antipsychotics are preferred drugs over the conventional antipsychotics for the treatment as outcome of patients treated with conventional antipsychotics is unsatisfactory and adverse effects associated with them, in particular extrapyramidal adverse effects, can result in poor compliance 8.
    [Show full text]
  • WO 2011/064769 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 3 June 2011 (03.06.2011) WO 201 1/064769 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/506 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/70 (2006.01) A61P 5/24 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IL20 10/000976 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 22 November 2010 (22.1 1.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/264,025 24 November 2009 (24.1 1.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): YIS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, SUM RESEARCH DEVELOPMENT COMPANY OF TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, THE HEBREW UNIVERSITY OF JERUSALEM EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, LTD.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]